The Commission has signed a joint procurement framework contract with
the pharmaceutical company Gilead for the supply of up to 500,000
treatment courses of Veklury, the brand name for Remdesivir, and the
opportunity to increase supply beyond the 500,000 treatment courses.
There are 36 signatories of the Joint Procurement Agreement
participating in this joint procurement, including all EU countries,
the EEA countries of Norway and Iceland*, the UK, as well as six
candidate countries and potential candidates (Albania, the Republic of
North Macedonia, Montenegro, Serbia, Kosovo** and Bosnia and
Herzegovina). All participating countries can now place their orders to
procure Veklury directly. Veklury is at this stage the only medicine
with a conditional marketing authorisation in the EU for the treatment
of COVID-19 patients needing oxygen supply.
Read more at: Coronavirus: Remdesivir
with news about and related
to the EU, the Netherlands,
and Almere - Europe's most modern multi-cultural city
Showing posts with label Remdesivir. Show all posts
Showing posts with label Remdesivir. Show all posts
October 8, 2020
May 2, 2020
Remdesivir drug: Still many unanswered questions about remdesivir's potential as a COVID-19 treatment
The preliminary highlights from a major U.S. study suggesting an experimental drug can speed up the recovery of COVID-19 patients is exciting news that needs to be tempered with a healthy dose of caution until full details are released in a published study, say Canadian infectious disease experts.
Read more at:
https://www.cbc.ca/news/canada/edmonton/remdesivir-coronavirus-canadian-researchers-await-data-1.5552254
Read more at:
https://www.cbc.ca/news/canada/edmonton/remdesivir-coronavirus-canadian-researchers-await-data-1.5552254
Labels:
Coronavirus,
Drug,
Remdesivir,
Test,
Unreliable
Subscribe to:
Posts (Atom)